HIF1A and aspergillosis: For this reason, given the well-known beneficial effects of HIF-1α stabilization on disease outcomes and barrier function in animal models of intestinal inflammation (Colgan et al, 2015), we treated p47phox–/– mice with aspergillosis with dimethyloxalylglycine (DMOG)—a cell-permeable competitive inhibitor of prolyl hydroxylase (PHD) that stabilizes HIF-1α (Mole et al, 2003)—for 5 d.